Acquired Perforating Dermatosis: A Disorder Treatable with Mycophenolate Mofetil

Area of Science:

• Dermatology
• Immunology
• Nephrology

Background:

• Acquired perforating dermatosis (APD) is a severe skin condition often linked to diabetes and chronic kidney disease.
• APD causes disabling pruritus and ulcerating lesions, frequently unresponsive to conventional treatments.
• Nearly 10% of patients with renal disease are affected by APD.

Purpose of the Study:

• To evaluate the efficacy of mycophenolate mofetil (MMF) in treating severe acquired perforating dermatosis (APD) in patients with renal disease.
• To assess the safety and long-term effectiveness of MMF for APD management.

Main Methods:

• A study involving 32 patients with renal disease and severe APD.
• Treatment with mycophenolate mofetil (MMF).
• Disease severity assessed using the Eczema Area and Severity Index (EASI).

Main Results:

• Significant reduction in EASI scores from 31 to 3 within 3 months of MMF treatment.
• Sustained improvement in disease severity for up to 2 years, even with reduced MMF dosage.
• MMF demonstrated a favorable safety profile in this patient cohort.

Conclusions:

• Mycophenolate mofetil (MMF) is a safe and effective treatment for severe acquired perforating dermatosis (APD), particularly in patients with renal disease.
• MMF offers both short- and intermediate-term therapeutic benefits for APD.
• The study supports an autoimmune etiology for APD.